Health

Healthcare Economist was once again named one of the top economics blogs (#37) by FeedSpot. What other blogs were in the top 100? Check out the full list here. I was also ranked as one of the top economic blogs of 2026 by the Intelligent Economist as well.

How to communicate your health policy research. JP Morgan employees sue employer over health benefits. Are insurers’ promised preauthorization reforms becoming a reality? The secret to happiness? Let’s gooooo!

That is the title of a new paper published in Future Oncology with co-authors Tara Graff,Savreet Bains Chawla,Monika Jun,Nicole Heaps,Abualbishr Alshreef,David Tybor,Donald C. Moore,Nadine Zawadzki, and Kathryn Spurrier. The abstract is below: Aim To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse…

What factors should a physician consider on whether to use a new medical innovation on a patient? Of course, the potential benefits and risk of the innovation to the patient matter most. But another factor could play a role in the physician’s decision: malpractice liability. Specifically, (i) is the use of the innovation more likely…

I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…